Welcome

HOPE Research Institute is an independent, multi-specialty, research organization dedicated to conducting clinical research trials in partnership with Valley physicians and their patients.

With NIH certified investigators and ACRP certified study coordinators, HOPE Research Institute can conduct inpatient and outpatient clinical trials across the Phoenix area.

HOPE Research Institute, LLC, conducts clinical research projects for the pharmaceutical industry in the Valley of the Sun, Phoenix, Arizona. Under the careful supervision of trained, experienced physicians, Valley residents can participate in studies of investigational products. HOPE's research facility is conveniently located in North Phoenix on Union Hills Drive near the intersection of freeways 51 and 101. Participants are placed into studies in a variety of therapeutic areas, depending on their eligibility. HOPE's therapeutic ares include: Family / Internal Medicine, Gastroenterology, Neurology / Sleep Medicine, Ophthalmology, Orthopedics / Orthopedic Surgery, Pain Management, Podiatry, Urology, or Women's Health. Study participation can be a positive experience for both the physician and the patient that may provide opportunities for learning, healthcare, and the betterment of our society.

Health and Clinical Research - Latest Headlines

Food and Drug Administration--Press Releases

FDA approves a new silicone gel-filled breast implant - 14 Jun 2013The U.S. Food and Drug Administration today approved the MemoryShape Breast Implant to increase breast size (augmentation) for use in women at least 22 years old and to rebuild breast tissue (reconstruction) in women of any age. The MemoryShape Breast Implants are manufactured by Mentor Worldwide LLC.
FDA approves Xgeva to treat giant cell tumor of the bone - 13 Jun 2013The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancerous tumor.
FDA approves two drugs, companion diagnostic test for advanced skin cancer - 29 May 2013The U.S. Food and Drug Administration today approved two new drugs, Tafinlar (dabrafenib) and Mekinist (trametinib), for patients with advanced (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer.
FDA announces import of injectable nutrition drugs - 29 May 2013The U.S. Food and Drug Administration announced today that injectable drugs used in total parenteral nutrition (TPN) in critical shortage will be imported into the United States and available to patients this week.
FDA clears first blood tracking device that uses Radio Frequency Identification technology - 28 May 2013iTrace for Blood Centers, (Version 1.0.924.0), the first application to use Radio Frequency Identification (RFID) technology in blood establishments to assist in enhancing blood safety by preventing the release of unsuitable blood components, was cleared today by the U.S. Food and Drug Administration.

NIH News Releases

Participants sought for NIH study of adrenal disorder - 18 Jun 2013Study will examine effectiveness of a new hormone pump.
NIH to fund collaborations with industry to identify new uses for existing compounds - 18 Jun 2013Crowdsourcing initiative will enable exploration of potential treatments in eight disease areas
NIH launches Dietary Supplement Label Database - 17 Jun 2013Searchable collection contains product information and ingredients from labels of dietary supplements sold in U.S.
NCATS to announce awards for Discovering New Therapeutic Uses for Existing Molecules program - 14 Jun 2013Media briefing with NCATS Director Christopher P. Austin, M.D.

World Health Organization News

WHO interim guidance on the use of bedaquiline to treat MDR-TB - 13 Jun 201313 June 2013 -- WHO estimates that up to half a million new cases of multidrug-resistant tuberculosis (MDR-TB) occur worldwide, each year. For the first time in over 40 years, a new TB drug with a novel mechanism of action - bedaquiline- is available, and was granted accelerated approval by the United States Food and Drug Administration in December 2012.
WHO: More voluntary blood donors needed - 12 Jun 201312 June 2013 -- On World Blood Donor Day, 14 June, WHO calls for all countries to obtain 100% of their supplies of blood and blood products from voluntary unpaid blood donors by 2020.
Middle East respiratory syndrome coronavirus: Joint Kingdom of Saudi Arabia/WHO mission - 10 Jun 201310 June 2013 -- Between 4 and 9 June 2013, a joint mission of the Kingdom of Saudi Arabia and the World Health Organization (WHO) met in Riyadh to assess the situation due to a new coronavirus in the Kingdom. This virus has recently been named the Middle East respiratory syndrome coronavirus (MERS-CoV). It is a new, emerging virus that is distantly related to the virus that caused SARS.
WHO issues guidance on emerging double threat of childhood obesity and undernutrition in low- and middle-income countries - 05 Jun 20135 June 2013 -- Many low- and middle-income countries are neglecting overweight and obesity as major health threats, with policies in place to tackle undernutrition, but lack policies to halt the growing burden of diseases due to the rise of overweight, and obesity, according to new information released by WHO today.